TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Last trade$94.79
Day change+$2.58 (+2.80%)
Day range$90.57 – $95.76
Volume525,118
Market cap$3.20B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.2B
Price / earnings
22.17×
Price / book
5.82×
Price / sales
4.4×
EV / sales
4.91×
EV / EBITDA
28.15×
Profitability
Earnings per share
$4.16
Return on assets
9.52%
Return on equity
26.23%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.56×
Current ratio
4.53×
Quick ratio
4.15×
Cash ratio
3.22×
Cash flow
Price / cash flow
28.51×
Price / free cash flow
71.66×
Free cash flow
$44.7M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TMDX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$203.01M
$189.95M
$173.93M
$160.76M
$143.82M
$157.37M
$143.54M
$121.62M
Cost of revenue
$84.35M
$76.75M
$72.77M
$67.35M
$59.25M
$60.78M
$55.31M
$49.61M
Gross profit
$118.66M
$113.2M
$101.16M
$93.41M
$84.58M
$96.59M
$88.23M
$72.01M
Selling, general and administrative
$61.33M
$57.83M
$62.99M
$51.44M
$46.02M
$44.09M
$43.63M
$46.91M
Research and development
$29.18M
$31.63M
$24.88M
$20.7M
$15.26M
$15.93M
$17.16M
$16.46M
Total operating expenses
$90.52M
$89.46M
$87.86M
$72.14M
$61.28M
$60.02M
$60.79M
$63.37M
Operating income
$28.14M
$23.74M
$13.3M
$21.27M
$23.3M
$36.57M
$27.44M
$8.64M
Interest expense
-$7.27M
-$7.23M
-$7.17M
-$3.35M
-$3.49M
-$3.48M
-$3.46M
-$3.57M
Income before taxes
$24.1M
$19.41M
$8.49M
$21.63M
$23.03M
$36.18M
$26.68M
$6.99M
Income taxes
$7.03M
$4.72M
$1.17M
-$83.75M
-$1.29M
$1.28M
$994K
$132K
Net income
$17.07M
$14.68M
$7.32M
$105.38M
$24.32M
$34.91M
$25.68M
$6.86M
Net income attributable to common shareholders
$17.07M
$14.68M
$7.32M
$105.38M
$24.32M
$34.91M
$25.68M
$6.86M
EBITDA
$38.98M
$33.98M
$25.16M
$28.74M
$30.15M
$43.3M
$33.58M
$14.32M
Basic earnings per share
$0.49
$0.42
$0.21
$3.08
$0.71
$1.03
$0.76
$0.20
Diluted earnings per share
$0.46
$0.41
$0.20
$2.57
$0.66
$0.92
$0.70
$0.19
Recent news
Company coverage with links to the original publishers.
TransMedics reported Q3 2026 revenue of $203.01 million, up 41.2% year-over-year, beating the consensus estimate of $181.81 million by 11.66%. EPS came in at $0.51, delivering an 88.89% surprise versus the $0.27 consensus estimate. Key metrics showed strong performance across most segments, particularly in international markets and service revenue. However, the stock has declined 10.3% over the past month and carries a Zacks Rank #3 (Hold) rating.
TransMedics (TMDX) is positioned for growth driven by its innovative Organ Care System (OCS) technology and pipeline expansion, including Gen 3.0 platform and international expansion. However, the company faces headwinds from declining gross margins (down 180 basis points to 59.6%) and reduced 2026 operating margin guidance, as it prioritizes revenue growth over near-term profitability.
TransMedics has selected Gogo Galileo to provide high-performance connectivity across its fleet of 22 Embraer Phenom 300E aircraft used for time-critical organ transport missions. The Gogo Galileo HDX system, powered by Eutelsat OneWeb's LEO satellite network, will be installed on all aircraft by 2027, making TransMedics the first organ transplant company to achieve full fleet connectivity. The system will enable real-time monitoring of organs during transport with enhanced cybersecurity and redundancy features.
TransMedics (TMDX) reported Q2 2026 earnings that missed estimates by 12%, with EPS down 52.2% year-over-year to $0.44. However, revenues grew 20.7% to $189.9 million, driven by strong service revenue growth of 28.6%. The company raised its 2026 revenue guidance but lowered adjusted operating margin expectations due to accelerated OCS Kidney investments. Analyst estimates have shifted downward by 31.5% since the earnings release, resulting in a Zacks Rank #5 (Strong Sell) rating.
Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of TransMedics Group, Inc. The firm is seeking shareholders to join the investigation and offers legal representation for affected investors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.